GSK To Acquire 35Pharma For $950 Mln
(RTTNews) - GSK plc (GSK, GSK.L, GS71.DE) has entered an agreement to acquire 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of protein-based therapeutics. GSK will acquire 100% of the equity of 35Pharma Inc. for $950 million, payable in cash at closing.
The acquisition includes HS235, an investigational medicine that has completed phase I healthy volunteer clinical trials with studies to start imminently in pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction.
At last close, GSK shares were trading at 2,201.00 pence, down 0.23%.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.